Metropolis Q4 net profit up by 8%, revenue grows 11%

Metropolis Healthcare on Tuesday announced an 8% year-on-year growth in its net profit for the fourth quarter of the financial year 2024 at ₹36.1 crore. The company recorded an 11% YoY growth in its revenue from operations to ₹313 crore. Shares of the company were trading over 5% higher on Wednesday.

Metropolis’ earnings before interest, tax, depreciation, and amortisation (EBITDA) for the fourth quarter grew 15.3% YoY to ₹79.7 crore. The EBITDA margin during the quarter saw an expansion of 100 basis points (bps) YoY to 25.5%. However, the net profit margin in the quarter declined by 30 bps to 11.6%.

Metropolis’ core business revenue saw a growth of 15% YoY to ₹308 crore while its core business patient volume rose 7% to 29.8 lakh. In the fourth quarter, the company witnessed a 16.5% YoY growth in revenue from specialized tests while the volume for the same grew by 10.5% YoY. Business-to-consumer (B2C) revenue saw a growth of 19.6% YoY while B2B revenue grew by 11.1% YoY.

In FY24, Metropolis’ net profit declined by 10.7% YoY to ₹128.1 crore. The company’s revenue from operations grew by 3.6% YoY to ₹1,189.5 crore. The company’s reported EBITDA for the year was lower by 2.8% YoY at ₹284.6 crore. EBITDA margin during the year contracted to 23.9% compared to 25.5% in the year before.

Ameera Shah, managing director of Metropolis Healthcare said as the firm progresses with its Metropolis 3.0 strategy, along with organic growth via existing network and expansion, mergers and acquisitions (M&A) will be pivotal in elevating its position. “Our goal is to enhance our technical testing capabilities and enter new markets, bolstering our strengths and ensuring sustainable growth,” she said.

Shares of the company have risen by over 20% since the beginning of the year. The stock has gained nearly 62% in the last one year.